Itraconazole Oral Solution

Itraconazole Oral Solution

Form: Oral Solution

Strength: 10 mg/mL

Reference Brands: Sporanox(US & EU)

Category: Anti-fungal

Itraconazole oral solution is approved in the EU and US for treating fungal infections. In the EU, Janssen’s Sporanox oral solution is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA-approved Sporanox oral solution and generics are backed by comprehensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed regulatory dossiers for approval and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz, your trusted partner in regulatory solutions, ensuring efficient market access and adherence to regulatory standards for itraconazole oral solutions.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Nystatin Oral Suspensions/Tablets

Strength: Tab: 500,000 units, 1,000,000 units; Sus: 100,000 units/mL, 500,000 units/5 mL

Form: Tablets/Suspensions

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Nystatin Topical Creams and Ointments

Strength: 100,000 units/g, 100,000–300,000 units/g

Form: Topical Creams and Ointments

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Micafungin Intravenous (IV) Powder

Strength: 50 mg, 100 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Mycamine(US & EU)

View Details Get Enquiry
Anidulafungin injection

Strength: 50 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Eraxis(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.